Compare EPM & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | MDWD |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 230.7M |
| IPO Year | 1996 | 2014 |
| Metric | EPM | MDWD |
|---|---|---|
| Price | $4.07 | $18.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.75 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 431.3K | 96.8K |
| Earning Date | 11-11-2025 | 11-20-2025 |
| Dividend Yield | ★ 11.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,232,000.00 | $20,932,000.00 |
| Revenue This Year | N/A | $15.89 |
| Revenue Next Year | $2.97 | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | $3.71 | $14.14 |
| 52 Week High | $5.70 | $22.51 |
| Indicator | EPM | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 59.99 |
| Support Level | $4.02 | $18.71 |
| Resistance Level | $4.27 | $19.63 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 62.00 | 79.22 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.